Evaluation of in vitro Antiurolithiatic Potential of Ethanolic Leaf Extract of Langerstromia specoisa
-
Published:2022-07-16
Issue:
Volume:
Page:150-154
-
ISSN:0975-4385
-
Container-title:Research Journal of Pharmacognosy and Phytochemistry
-
language:en
-
Short-container-title:RJPP
Author:
R Chandrasekar1, R. Pavithra1, B. Vandana1, R. Babitha1, S. Tejoprasanna1, B. Sandeep1, G. Deepika1, Babu M. Niranjan2
Affiliation:
1. Associate Professor, Department of Pharmacognosy, Seven Hills College of Pharmacy, Venkatramapuram, Tirupati, Chittoor, Andhrapradesh, India. 2. Professor, Department of Pharmacognosy, Seven Hills College of Pharmacy, Venkatramapuram, Tirupati, Chittoor, Andhrapradesh, India.
Abstract
Urolithiasis is a common disease, affecting a large number of people worldwide, affecting all the age groups from youngsters to old people. Urolithiasis is one of the most severe urologic disorders which are most prevalent in developed and developing countries. Lagerstroemia speciosa, belongs to the group of Lythraceae family, commonly called as crape myrtle is a medicinal plant that has traditionally been used as an antidiabetic, lowering blood glucose levels in the body. Banaba is the common name of Lagerstroemia speciosa. The current study was investigated for the in vitro antiurolithiatic potential of Langerstromia specoisa leaf extract (LSEE) against calcium oxalate (CaOx) urolithiasis. The mechanism of stone formation involves supersaturation, crystal nucleation, precipitation, crystal growth and aggregation of crystals. The CaOx crystal was characterized by FT-IR analysis. LSEE significantly inhibited the stone formation, nucleation, growth and aggregation of CaOx crystals. FT-IR characterization was used for analyzing the formation of calcium oxalate crystals, which will be used in growth and aggregation assays. LSEE has significant antiurolithiatic activity in vitro against CaOx urolithiasis, which could be attributed to its flavonoids, polyphenolic content, saponins and tannins.
Publisher
A and V Publications
Reference20 articles.
1. Thongprayoon C, Krambeck AE, Rule AD. Determining the true burden of kidney stone disease. Nat Rev Nephrol. 2020 doi: 10.1038/s41581-020-0320-7. 2. Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. World J Urol. 2017; 35:1301–20. 3. Lohiya A, Kant S Kapil A, Gupta SK, Misra P, Rai SK. Population-based estimate of urinary stones from Ballabgarh, northern India. Natl Med J India. 2017; 30:198–200. 4. Romero V, Akpinar H and Assimos D G, Kidney stones: A global picture of prevalence, incidence, and associated risk factors, Rev Urol, 2010, 12(2-3), e86–e96. 5. Parmar MS, Kidney stones, BMJ, 2004, 328(7453), 1420–1424.
|
|